Biocept Inc. buy klostergang
Start price
01.07.15
/
50%
€81,567
Target price
07.12.15
€81,000
Performance (%)
-48.63%
End price
07.12.15
€41,904
Summary
This prediction ended on 07.12.15 with a price of €41,904. Massive losses of -48.63% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biocept Inc. | - | - | - | - |
| iShares Core DAX® | 0,99 % | 8,31 % | 7,03 % | 49,79 % |
| iShares Nasdaq 100 | 2,07 % | 16,77 % | 35,95 % | 96,63 % |
| iShares Nikkei 225® | 2,27 % | 15,61 % | 46,57 % | 69,05 % |
| iShares S&P 500 | 1,04 % | 11,08 % | 26,46 % | 68,09 % |
Comments by klostergang for this prediction
In the thread Biocept Inc. diskutieren
An emerging player in the liquid biopsy space :
Biocept Inc is a cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample or liquid biopsy.
(Vom Mitglied beendet)